血小板C型凝集素样受体-2参与肿瘤血行转移的研究进展

Progress in platelet-activating C-type lectin-like receptor-2 and hematogenous metastasis of tumor

肿瘤转移过程极其复杂,研究发现血小板与肿瘤血行转移密切相关,血小板可释放生物活性因子协助肿瘤细胞逃脱免疫监视,促进肿瘤细胞的上皮-间质转化(epithelial-mesenchymal transition,EMT)、增殖和侵袭能力,以加快肿瘤血行转移。近年来研究发现,血小板表面的C型凝集素样受体2(C-type lectin-like receptor-2,CLEC-2)与其配体平足蛋白(podoplanin,PDPN)结合后可激活血小板参与肿瘤的生长、迁徙和转移。应用抗CLEC-2抗体或阻断CLEC-2与PDPN的结合可能是抗肿瘤转移的一个新的研究方向,本文就CLEC-2在肿瘤血行转移中的作用及其临床应用前景进行综述。

The process of tumor metastasis is extremely complicated. The growing evidence indicates that platelets are closely involved in hematogenous metastasis of tumors. Platelets can secret an array of bioactive factors to help cancer cells evading immune surveillance and natural killer cell-mediated cytotoxicity, induce epithelial- mesenchymal transition （EMT）, proliferation, invasion of tumor cells, and subsequently promote cancer progression. Recent studies have showed that the interaction between platelet-activating C-type lectin-like receptor-2 （CLEC-2） and its ligand podoplanin （PDPN） can activate platelets and affect the proliferation, migration, and metastasis of tumor cells. Therefore, using anti-CLEC-2 antibody and blocking the CLEC-2/PDPN interaction maybe the novel anti- cancer treatments. This review illuminates the role of CLEC-2 in hematogenous metastasis of tumors and its clinical application prospect.